

Special Issue

Unraveling the Molecular Mechanisms of Heart and Skeletal Muscle Pathologies

Message from the Guest Editors

This Special Issue of *Biomedicines* focuses on recent advances in the elucidation of the molecular mechanisms underlying cardiac and skeletal pathologies as a basis for the development of novel therapeutic strategies. Thus, we welcome original research articles and reviews that provide new insights into the molecular mechanisms underlying cardiac and skeletal muscle disorders, including the identification of novel therapeutic targets and pre-clinical testing of potential therapeutic strategies to improve treatment and cure. Areas of interest include, but are not limited, to, the following topics:

- The use of pre-clinical models (animal and cell-based models) to provide a better understanding of the molecular pathways that lead to the onset and progression of pathologies affecting cardiac and/or skeletal muscle;
- The identification of novel therapeutic targets;
- Pre-clinical testing of potential therapies to improve treatment and cure.

Guest Editors

Dr. Marie-Louise Bang

Institute of Genetic and Biomedical Research—National Research Council (IRGB-CNR), Milan Unit at Humanitas Research Hospital, Milan, Italy

Prof. Dr. Edoardo Malfatti

Centre de Référence de Pathologie Neuromusculaire Nord-Est-Ile-de-France, Université Paris Est, U955 INSERM, EnvA, EFS, IMRB, F-94010 and APHP, Henri Mondor Hospital, 94010 Créteil, France

Deadline for manuscript submissions

closed (31 January 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/185976

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).